- €26.61m
- €38.53m
- €20.96m
Brief: Genoway Sees 2023 EBITDA Margin Above 20%
Brief: GenOway Sets Up JV In Shanghai
Brief: Genoway H1 EBITDA Rises To 2.3 Million Euros
Brief: Genoway H1 Total Revenue Up At 9.3 Million Euros
Brief: GenOway FY EBITDA Up At 3.2 Million Euros
Brief: Genoway FY Sales Up At Eur 17.1 Mln
Brief: genOway H1 Net Result Turns To Profit Of EUR 0.2 Mln
Brief: genOway, Sigma-Aldrich Expand CRISPR/CAS9 Strategic Alliance
Brief: Genoway and Sigma-Aldrich Expand Their CRISPR/CAS9 Strategic Alliance
Brief: Sigma-Aldrich And Genoway Expand Their CRISPR/Cas9 Strategic Alliance
Brief: GenOway H1 Revenue Up At 7.8 Million Euros
Brief: GenOway FY EBITDA Up At EUR 1.5 Million
Brief: genOway Grants CRISPR/Cas9 License To U.K. Academic Research Funder
Brief: Genoway Licenses Its Crispr/Cas9 Technology To UKRI
Brief: Genoway Signs A 0.4 Mln Euros Framework Contract With Pharmaceutical Company
Brief: Genoway H1 Net Loss Narrows To EUR 0.7 Mln
Brief: Genoway H1 Revenue Up At EUR 6.2 Million
Brief: genOway: NextStage AM Becomes genOway's First Shareholder With A 12.4% Stake
Brief: Genoway Plans A Capital Increase Of About 5 Million Euros